Preferred Label : Raltegravir Potassium;
NCIt synonyms : N-[(4-Fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[1-methyl-1-[[ (5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino]ethyl]-6-oxo-4-pyrimidinecarboxamide
Monopotassium Salt;
NCIt definition : The orally bioavailable potassium salt of a human immunodeficiency virus (HIV) integrase
strand transfer inhibitor (HIV-1 INSTI) with HIV-1 antiviral activity. Raltegravir
binds to and inhibits integrase, an HIV enzyme that inserts viral genetic material
into the genetic material of the infected human cell. Inhibition of integrase prevents
insertion of HIV DNA into the human DNA genome, thus blocking HIV replication.;
UNII : 43Y000U234;
InChIKey : IFUKBHBISRAZTF-UHFFFAOYSA-M;
CAS number : 871038-72-1;
Drug name : Isentress;
Chemical formula : C20H20FN6O5.K;
Origin ID : C73823;
UMLS CUI : C1966407;
Currated CISMeF NLP mapping
Semantic type(s)
UMLS correspondences (same concept)
concept_is_in_subset
has_free_acid_or_base_form
is_salt_form_of
https://www.has-sante.fr/portail/jcms/c_2967178/fr/isentress
2019
true
France
French
adolescent
child
human immunodeficiency virus i infection
Raltegravir Potassium
drug therapy, combination
Raltegravir Potassium
Raltegravir Potassium
insurance, health, reimbursement
treatment outcome
administration, oral
raltegravir
adult
HIV integrase inhibitors
hiv infections
HIV-1
antiretroviral therapy, highly active
HIV integrase inhibitors
evaluation of the transparency committee
---
http://www.has-sante.fr/portail/jcms/c_2580837/fr/isentress
http://www.has-sante.fr/portail/jcms/c_2580837/fr/isentress-100-mg-raltegravir-granules-pour-suspension-buvable-antiretroviral
2015
false
France
French
child
human immunodeficiency virus i infection
Raltegravir Potassium
drug therapy, combination
infant
infant, newborn
Raltegravir Potassium
Raltegravir Potassium
guidelines for drug use
insurance, health, reimbursement
treatment outcome
administration, oral
raltegravir
HIV integrase inhibitors
hiv infections
HIV-1
antiretroviral therapy, highly active
HIV integrase inhibitors
evaluation of the transparency committee
---
http://www.has-sante.fr/portail/jcms/c_1776508/fr/isentress
http://www.has-sante.fr/portail/jcms/c_1701815/fr/isentress
http://www.has-sante.fr/portail/jcms/c_1702552/fr/isentress
http://www.has-sante.fr/portail/jcms/c_1001255/isentress
2014
false
France
French
adolescent
child
human immunodeficiency virus i infection
Raltegravir Potassium
drug therapy, combination
Raltegravir Potassium
Raltegravir Potassium
insurance, health, reimbursement
treatment outcome
administration, oral
raltegravir
adult
HIV integrase inhibitors
hiv infections
HIV-1
antiretroviral therapy, highly active
HIV integrase inhibitors
evaluation of the transparency committee
---